1. In this randomized controlled trial, aficamten significantly improved peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) ...
Click here to read this study in The New England Journal of Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. In this randomized controlled trial, patients with transthyretin (TTR) amyloid cardiomyopathy exposed to acoramidis had slower disease progression than ...
©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. ...
1. In this randomized controlled trial, the antibody NI006 for the treatment of transthyretin amyloid cardiomyopathy (ATTR) showed no associated drug-related ...
1. In this randomized controlled trial, patients who received transcatheter repair of mitral regurgitation secondary to cardiomyopathy had good safety ...
1. In this randomized controlled trial, patients who received transcatheter repair of mitral regurgitation secondary to cardiomyopathy had good safety ...
1. Compared to placebo, patients treated with mavacamten for 30 weeks showed significant improvements on the KCC Questionnaire which evaluates ...
1. In this study of White and African American adults who had unexplained sudden cardiac death, nearly 20% of individuals ...
